|
| Author (yr) | Study | Setting | Pts | Treatment | RR (%) | PFS (mos) | OS (mos) |
|
| Mok et al. (2009) [57] | IPASS | 1st line, clinically selected | 1217 | Gefitinib versus Carboplatin +
Paclitaxel | 43 versus 32.3 () | 5.7 versus 5.8 HR: 0.74, 95% CI: 0.65–0.85, | 18.6 versus 17.3 HR: 0.91, 95% CI: 0.76–1.10 |
| | Subgroup of EGFR mutated | 261 | | 71.2 versus 47.3 () | 9.5 versus 6.3 HR: 0.48, 95% CI: 0.36–0.64, | HR: 0.78, 95% CI 0.50–1.20 |
|
| J. S. Lee et al. (2009) [58] | FIRST SIGNAL | 1st line, clinically selected | 309 | Gefitinib versus Cisplatin +
Gemcitabine | 53.5 versus 45.3 () | 6.1 versus 6.6 HR: 0.813, 95% CI: 0.641–1.031, | 21.3 versus 23.3 HR: 1.003, 95% CI: 0.749–1.343, |
| | Subgroup of EGFR mutated | 42 | | 84.6 versus 37.5 () | 8.5 versus 6.7 HR: 0.613, 95% CI: 0.308–1.221, | 30.6 versus 26.5 HR: 0.823, 95% CI: 0.352–1.922, |
|
| Mitsudomi et al. (2010) [59] | WJTOG 3405 | 1st line, EGFR mutated | 172 | Gefitinib versus Cisplatin +
Docetaxel | 62.1 versus 32.2 () | 9.2 versus 6.3 HR 0.489, 95% CI: 0.336–0.710, | 30.9 versus nr HR: 1.638, 95% CI 0.749–3.582, |
|
| Maemondo et al. (2010) [60] | NEJ002 | 1st line, EGFR mutated | 230 | Gefitinib versus Carboplatin +
Paclitaxel | 73.7 versus 30.7 () | 10.8 versus 5.4 HR 0.30, 95% CI: 0.22–0.41, | 30.5 versus 23.6 |
|
